

# CITATION REPORT

List of articles citing

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

DOI: 10.1128/jvi.77.18.10078-10087.2003  
Journal of Virology, 2003, 77, 10078-87.

**Source:** <https://exaly.com/paper-pdf/35681329/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper  | IF  | Citations |
|-----|--|-----|-----------|
| 138 | Adenoviruses as vaccine vectors. <b>2004</b> , 10, 616-29  |     | 444       |
| 137 | A call for replicating vector prime-protein boost strategies in HIV vaccine design. <b>2004</b> , 3, S105-17   |     | 33        |
| 136 | Pulmonary DNA vaccination: concepts, possibilities and perspectives. <b>2005</b> , 107, 1-29   |     | 63        |
| 135 | Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. <b>2005</b> , 331, 82-93   |     | 39        |
| 134 | Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. <b>2005</b> , 3, 157-81   |     | 17        |
| 133 | Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. <i>Gene Therapy</i> , <b>2005</b> , 12, 1769-77   | 4   | 43        |
| 132 | Adenovirus as vehicle for anticancer genetic immunotherapy. <i>Gene Therapy</i> , <b>2005</b> , 12 Suppl 1, S84-91   | 4   | 32        |
| 131 | Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. <b>2005</b> , 175, 6032-41  |     | 63        |
| 130 | Adenoviral vectors for mucosal vaccination against infectious diseases. <b>2005</b> , 18, 283-91   |     | 59        |
| 129 | Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. <i>Journal of Virology</i> , <b>2005</b> , 79, 10200-9 | 6.6 | 84        |
| 128 | Adenovirus vector-based vaccines for human immunodeficiency virus type 1. <i>Human Gene Therapy</i> , <b>2005</b> , 16, 149-56   | 4.8 | 141       |
| 127 | Intranasal delivery of vaccines against HIV. <b>2006</b> , 3, 247-59   |     | 21        |
| 126 | HIV vaccines: can mucosal CD4 T cells be protected?. <b>2006</b> , 1, 272-6  |     |           |
| 125 | Rational design of gene-based vaccines. <b>2006</b> , 208, 283-9   |     | 57        |
| 124 | Mucosal vaccines: the promise and the challenge. <b>2006</b> , 6, 148-58   |     | 881       |
| 123 | Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. <b>2006</b> , 8, 92-104                                 |     | 50        |
| 122 | Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery. <i>Journal of Virology</i> , <b>2006</b> , 80, 12324-31   | 6.6 | 13        |

|     |  |     |     |
|-----|--|-----|-----|
| 121 | A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. <b>2006</b> , 14, 662-72   |     | 43  |
| 120 | Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin. <b>2007</b> , 14, 767-74   |     | 21  |
| 119 | Mucosal Adjuvants and Delivery Systems. 295-326  |     | 2   |
| 118 | Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. <i>Vaccine</i> , <b>2007</b> , 25, 2074-84   | 4.1 | 54  |
| 117 | Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). <i>Vaccine</i> , <b>2007</b> , 25, 8021-35 | 4.1 | 41  |
| 116 | Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. <i>Vaccine</i> , <b>2007</b> , 25, 8598-610   | 4.1 | 157 |
| 115 | Pulmonary vaccine delivery. <b>2007</b> , 6, 213-26  |     | 104 |
| 114 | Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. <b>2007</b> , 2, 81-6  |     | 86  |
| 113 | Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector. <b>2008</b> , 6, 5  |     | 28  |
| 112 | From nose to brain: understanding transport capacity and transport rate of drugs. <b>2008</b> , 5, 1159-68   |     | 112 |
| 111 | Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. <i>Gene Therapy</i> , <b>2008</b> , 15, 298-308   | 4   | 28  |
| 110 | Adenovirus-vectored vaccines. <i>Expert Opinion on Therapeutic Patents</i> , <b>2008</b> , 18, 293-307   | 6.8 | 5   |
| 109 | Immune responses of recombinant adenoviruses expressing immunodominant epitopes against Japanese encephalitis virus. <i>Vaccine</i> , <b>2008</b> , 26, 5802-7   | 4.1 | 8   |
| 108 | A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. <b>2008</b> , 180, 6159-67   |     | 24  |
| 107 | Recent patents review on intranasal administration for CNS drug delivery. <b>2008</b> , 2, 25-40   |     | 73  |
| 106 | Alternative vaccine delivery methods. <b>2008</b> , 1357-1392  |     | 8   |
| 105 | Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. <b>2009</b> , 8, 469-81  |     | 34  |
| 104 | Use of adenovirus in vaccines for HIV. <b>2009</b> , 275-93  |     | 9   |

|     |   |     |    |
|-----|---|-----|----|
| 103 | Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. <i>Journal of Virology</i> , <b>2009</b> , 83, 748-56  | 6.6 | 25 |
| 102 | Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. <b>2009</b> , 395, 182-9   |     | 34 |
| 101 | An adenoviral vector-based mucosal vaccine is effective in protection against botulism. <i>Gene Therapy</i> , <b>2009</b> , 16, 367-75  | 4   | 34 |
| 100 | Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. <b>2009</b> , 183, 7851-9       |     | 80 |
| 99  | Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. <b>2009</b> , 390, 937-41  |     | 34 |
| 98  | Lentiviral vectors for HIV disease prevention and treatment. <i>Vaccine</i> , <b>2009</b> , 27, 3443-9  | 4.1 | 12 |
| 97  | A recombinant adenovirus prime-virus-like particle boost regimen elicits effective and specific immunities against norovirus in mice. <i>Vaccine</i> , <b>2009</b> , 27, 5233-8   | 4.1 | 16 |
| 96  | Dendritic Cells. <b>2009</b> ,  |     | 2  |
| 95  | Strategies to overcome host immunity to adenovirus vectors in vaccine development. <b>2009</b> , 8, 761-77  |     | 85 |
| 94  | Update on mucosal HIV vaccine vectors. <b>2010</b> , 5, 397-403   |     | 13 |
| 93  | Production of adenovirus vectors and their use as a delivery system for influenza vaccines. <b>2010</b> , 10, 1469-87   |     | 49 |
| 92  | Neuroinflammation resulting from covert brain invasion by common viruses - a potential role in local and global neurodegeneration. <b>2010</b> , 75, 204-13   |     | 23 |
| 91  | An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. <i>Vaccine</i> , <b>2010</b> , 28, 1952-61   | 4.1 | 7  |
| 90  | Persistence of mucosal and systemic immune responses following sublingual immunization. <i>Vaccine</i> , <b>2010</b> , 28, 4175-80  | 4.1 | 30 |
| 89  | Potential use of a recombinant replication-defective adenovirus vector carrying the C-terminal portion of the P97 adhesin protein as a vaccine against Mycoplasma hyopneumoniae in swine. <i>Vaccine</i> , <b>2010</b> , 28, 4802-9 | 4.1 | 27 |
| 88  | Oral immunization with Porphyromonas gingivalis outer membrane protein and CpG oligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity. <b>2010</b> , 25, 178-89                                  |     | 19 |
| 87  | Bioadhesive delivery systems for mucosal vaccine delivery. <b>2010</b> , 18, 752-70   |     | 20 |
| 86  | Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. <b>2011</b> , 11, 739-50  |     | 26 |

|    |   |     |    |
|----|---|-----|----|
| 85 | Sublingual vaccination. <b>2011</b> , 7, 110-4  |     | 47 |
| 84 | M cell-targeted mucosal vaccine strategies. <b>2012</b> , 354, 39-52  |     | 26 |
| 83 | Intranasal inoculation with an adenovirus vaccine encoding ten repeats of AB-10 induces Th2 immune response against amyloid- $\beta$ in wild-type mouse. <b>2011</b> , 505, 128-33  |     | 5  |
| 82 | Protective anti- <i>Pseudomonas aeruginosa</i> humoral and cellular mucosal immunity by AdC7-mediated expression of the <i>P. aeruginosa</i> protein OprF. <i>Vaccine</i> , <b>2011</b> , 29, 2131-9  | 4.1 | 24 |
| 81 | Sublingually administered <i>Bacillus subtilis</i> cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. <i>Vaccine</i> , <b>2011</b> , 29, 4778-84  | 4.1 | 26 |
| 80 | Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier. <i>Vaccine</i> , <b>2011</b> , 29, 7080-9                                | 4.1 | 15 |
| 79 | Detection of intranasally delivered bone marrow-derived mesenchymal stromal cells in the lesioned mouse brain: a cautionary report. <b>2011</b> , 2011, 586586  |     | 14 |
| 78 | Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. <i>PLoS ONE</i> , <b>2011</b> , 6, e22605   | 3.7 | 17 |
| 77 | Intranasal anti-rabies DNA immunization promotes a Th1-related cytokine stimulation associated with plasmid survival time. <b>2011</b> , 42, 563-71   |     | 8  |
| 76 | Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases. <b>2011</b> , 10, 1539-52  |     | 18 |
| 75 | Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. <b>2011</b> , 8, 3  |     | 17 |
| 74 | Comparison of the protective efficacy of recombinant adenoviruses against classical swine fever. <b>2011</b> , 135, 43-9  |     | 8  |
| 73 | Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. <i>Journal of Virology</i> , <b>2011</b> , 85, 10529-41  | 6.6 | 32 |
| 72 | Nasal immunization with a fusion protein consisting of the hemagglutinin A antigenic region and the maltose-binding protein elicits CD11c(+) CD8(+) dendritic cells for induced long-term protective immunity. <b>2011</b> , 79, 895-904                                      |     | 8  |
| 71 | Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. <i>Viruses</i> , <b>2012</b> , 4, 2711-35  | 6.2 | 19 |
| 70 | Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. <i>Human Vaccines and Immunotherapeutics</i> , <b>2012</b> , 8, 425-30   | 4.4 | 15 |
| 69 | Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. <b>2012</b> , 19, 629-37 |     | 39 |
| 68 | The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza. <i>Human Vaccines and Immunotherapeutics</i> , <b>2012</b> , 8, 689-93  | 4.4 | 25 |

|    |   |     |     |
|----|---|-----|-----|
| 67 | Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants. <i>Vaccine</i> , <b>2012</b> , 30, 3666-74   | 4.1 | 4   |
| 66 | Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. <b>2012</b> , 106, 131-4   |     | 34  |
| 65 | Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. <b>2012</b> , 24, 117-28   |     | 10  |
| 64 | Sublingual immunization with an engineered <i>Bacillus subtilis</i> strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. <b>2012</b> , 14, 447-56   |     | 19  |
| 63 | Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. <b>2012</b> , 9, 215   |     | 33  |
| 62 | <i>Bacillus subtilis</i> : a temperature resistant and needle free delivery system of immunogens. <i>Human Vaccines and Immunotherapeutics</i> , <b>2012</b> , 8, 979-86  | 4.4 | 50  |
| 61 | Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. <i>PLoS ONE</i> , <b>2012</b> , 7, e33428  | 3.7 | 49  |
| 60 | An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. <i>Vaccine</i> , <b>2013</b> , 31, 2302-9  | 4.1 | 16  |
| 59 | Recombinant adenovirus expressing type Asia1 foot-and-mouth disease virus capsid proteins induces protective immunity against homologous virus challenge in mice. <b>2013</b> , 94, 796-802   |     | 8   |
| 58 | Alternative vaccine delivery methods. <b>2013</b> , 1200-1231   |     | 32  |
| 57 | The development of gene-based vectors for immunization. <b>2013</b> , 1232-1242   |     |     |
| 56 | Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. <b>2013</b> , 5, 172ra20   |     | 165 |
| 55 | Sublingual administration of <i>Lactobacillus rhamnosus</i> affects respiratory immune responses and facilitates protection against influenza virus infection in mice. <b>2013</b> , 98, 284-90   |     | 36  |
| 54 | Parenteral immunization with IpaB/IpaD protects mice against lethal pulmonary infection by <i>Shigella</i> . <i>Vaccine</i> , <b>2013</b> , 31, 2667-72   | 4.1 | 30  |
| 53 | Induction of mucosal immunity by intranasal immunization with recombinant adenovirus expressing major epitopes of Porcine circovirus-2 capsid protein. <b>2013</b> , 154, 48-53   |     | 3   |
| 52 | Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. <i>Journal of Virology</i> , <b>2013</b> , 87, 3668-77   | 6.6 | 48  |
| 51 | An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen. <b>2013</b> , 20, 1-8   |     | 17  |
| 50 | Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. <i>Journal of Virology</i> , <b>2014</b> , 88, 212-24 | 6.6 | 18  |

|    |  |     |    |
|----|--|-----|----|
| 49 | Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. <b>2014</b> , 105, 72-9   |     | 12 |
| 48 | Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. <i>Vaccine</i> , <b>2014</b> , 32, 2382-8   | 4.1 | 36 |
| 47 | Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. <b>2014</b> , 30, 1027-40  |     | 14 |
| 46 | Microprojection arrays to immunise at mucosal surfaces. <b>2014</b> , 196, 252-60  |     | 20 |
| 45 | A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice. <b>2014</b> , 62, 86-95  |     | 22 |
| 44 | Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1. <b>2014</b> , 35, 7896-908   |     | 14 |
| 43 | Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. <i>Gene Therapy</i> , <b>2014</b> , 21, 514-21  | 4   | 37 |
| 42 | Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice. <b>2015</b> , 12, 3073-80   |     | 13 |
| 41 | Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. <b>2015</b> , 145, 476-84   |     | 87 |
| 40 | The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced Amyloid $\beta$ Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. <b>2015</b> , 2015, 786501  |     | 4  |
| 39 | Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model. <b>2015</b> , 22, 430-9   |     | 16 |
| 38 | Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually. <i>Vaccine</i> , <b>2015</b> , 33, 5845-5853   | 4.1 | 15 |
| 37 | An adenoviral vector expressing lipoprotein A, a major antigen of Mycoplasma mycoides subspecies mycoides, elicits robust immune responses in mice. <i>Vaccine</i> , <b>2015</b> , 33, 141-8   | 4.1 | 2  |
| 36 | Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , <b>2017</b> , 27, 721-731   | 6.8 | 12 |
| 35 | Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I. <i>Human Gene Therapy</i> , <b>2017</b> , 28, 576-587 | 4.8 | 35 |
| 34 | Generation of infectious clone of bovine adenovirus type I expressing a visible marker gene. <i>Journal of Virological Methods</i> , <b>2018</b> , 261, 139-146  | 2.6 | 2  |
| 33 | Development of Gene-Based Vectors for Immunization. <b>2018</b> , 1305-1319.e8   |     | 1  |
| 32 | Evaluation of suitable antigens and adjuvant concentration for sublingual immunization to prevent periodontal disease. <i>Oral Science International</i> , <b>2019</b> , 16, 80-86   | 0.5 | 2  |

|    |  |      |     |
|----|--|------|-----|
| 31 | Mucosal vaccines and technology. <i>Clinical and Experimental Immunology</i> , <b>2019</b> , 196, 205-214  | 6.2  | 65  |
| 30 | Viral Vector Therapeutics Against Alzheimer's Disease. <b>2019</b> , 39-44   |      | 0   |
| 29 | Effect of exogenous expression of IFN- $\beta$ on the new world alphavirus replication and infection. <i>Future Virology</i> , <b>2019</b> , 14, 593-604   | 2.4  |     |
| 28 | Mucosal Vaccines for Oral Disease. <b>2020</b> , 649-661   |      | 2   |
| 27 | Recombinant Adenovirus Vectors as Mucosal Vaccines. <b>2020</b> , 419-444  |      | 2   |
| 26 | Viral infection and smell loss: The case of COVID-19. <i>Journal of Neurochemistry</i> , <b>2021</b> , 157, 930-943  | 6    | 21  |
| 25 | Neurological involvement of COVID-19: from neuroinvasion and neuroimmune crosstalk to long-term consequences. <i>Reviews in the Neurosciences</i> , <b>2021</b> , 32, 427-442                        | 4.7  | 6   |
| 24 | Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , <b>2021</b> , 170, 113-141  | 18.5 | 31  |
| 23 | A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. <i>Cell Reports</i> , <b>2021</b> , 36, 109400      | 10.6 | 35  |
| 22 | Concepts in Mucosal Immunity and Mucosal Vaccines. <b>2014</b> , 3-33  |      | 1   |
| 21 | Recombinant fowlpox virus vector-based vaccines: expression kinetics, dissemination and safety profile following intranasal delivery. <i>Journal of General Virology</i> , <b>2017</b> , 98, 496-505 | 4.9  | 9   |
| 20 | A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. <b>2020</b> ,                                       |      | 18  |
| 19 | Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 739-51  | 15.9 | 22  |
| 18 | Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. <i>PLoS ONE</i> , <b>2010</b> , 5, e13162         | 3.7  | 102 |
| 17 | Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. <i>PLoS ONE</i> , <b>2011</b> , 6, e27953   | 3.7  | 60  |
| 16 | Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. <i>PLoS ONE</i> , <b>2012</b> , 7, e32226  | 3.7  | 33  |
| 15 | Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e75460                       | 3.7  | 25  |
| 14 | Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge. <i>PLoS ONE</i> , <b>2014</b> , 9, e90001   | 3.7  | 11  |

|    |  |     |    |
|----|--|-----|----|
| 13 | Olfactory Loss and Dysfunction in Ciliopathies: Molecular Mechanisms and Potential Therapies. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 3103-3119   | 4.3 | 13 |
| 12 | Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. <i>Nano Research</i> , <b>2021</b> , 1-30  | 10  | 1  |
| 11 | Delivery of Molecular Therapeutics into the CNS and their Distribution within the Brain. <b>2006</b> , 121-131   |     |    |
| 10 | The development of gene-based vectors for immunization. <b>2008</b> , 1393-1401  |     | 1  |
| 9  | Comparison of Mucosal Immune Response after Oral, Nasal or Sublingual Immunization with an Outer Membrane Protein of Porphyromonas Gingivalis. <i>International Journal of Oral-Medical Sciences</i> , <b>2014</b> , 12, 121-128 | 0.2 | 3  |
| 8  | Lipopeptide-Based Vaccines. <b>2016</b> , 343-354  |     |    |
| 7  | COVID-19 Anosmia: High Prevalence, Plural Neuropathogenic Mechanisms, and Scarce Neurotropism of SARS-CoV-2?. <i>Viruses</i> , <b>2021</b> , 13,   | 6.2 | 4  |
| 6  | Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.. <i>Gene Therapy</i> , <b>2022</b> ,  | 4   | 0  |
| 5  | Intranasal COVID-19 vaccines: From bench to bed.. <i>EBioMedicine</i> , <b>2022</b> , 76, 103841   | 8.8 | 17 |
| 4  | COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.. <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 1-11  | 4.4 | 6  |
| 3  | Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.. <i>Inflammation Research</i> , <b>2022</b> , 1                                     | 7.2 |    |
| 2  | Preclinical Study on SARS-CoV-2 Sublingual Vaccine with RBD Antigen and Poly(I:C) Adjuvant in Cynomolgus Macaques.   |     | 0  |
| 1  | Olfactory Impairment in Disease and Aging. <b>2023</b> , 403-417   |     | 0  |